Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.
Berhanu
Aklile
A
SIGA Technologies, Inc., 4575 SW Research Way, Suite 230, Corvallis, OR 97333, USA.
King
David S
DS
Mosier
Stacie
S
Jordan
Robert
R
Jones
Kevin F
KF
Hruby
Dennis E
DE
Grosenbach
Douglas W
DW
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D054833:Isoindoles / Q000008:administration & dosage*; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D012900:Smallpox Vaccine / Q000009:adverse effects* / Q000276:immunology*; D016019:Survival Analysis; D014616:Vaccinia virus / Q000187:drug effects* / Q000276:immunology*; D010797:Phthalimides
D000914:Antibodies, Viral; D000998:Antiviral Agents; D001549:Benzamides; D054833:Isoindoles; D012900:Smallpox Vaccine; C505045:tecovirimat; D010797:Phthalimides